Delhi-based Dr Dangs selected as central lab for Covaxin human clinical trials

The lab has already started receiving samples from 50 to 100 subjects per day from various trial sites

Delhi-based Dr Dangs selected as central lab for Covaxin human clinical trials

New Delhi, July 23

A Delhi-based private laboratory has claimed that it has been selected as the central lab for human clinical trials of Covaxin, India’s indigenous COVID-19 vaccine candidate.

The vaccine is being developed and manufactured by Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology.

Dr Dangs Lab said on Wednesday that it had partnered with Bharat Biotech for conducting the trials.

“We are extremely privileged to announce that Dr Dangs Lab, New Delhi, has been provided the opportunity to serve the nation by being selected as the central lab for the Human Clinical trials of Covaxin; India’s indigenous COVID-19 vaccine being developed and manufactured by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV),” it said in a statement.

This is a “randomised, double blind, placebo controlled multi-centric clinical trial in India”, it added.

“Dr Dangs Lab is currently processing all samples for screening and safety for the various phases of this clinical trial, whereas all the efficacy studies will be performed in NIV (Pune),” the statement said.

The lab has already started receiving samples from 50 to 100 subjects per day from various trial sites for safety testing and will be increasing operations as per assigned timelines to cover 12 sites across the length and breadth of the country over this month, it added.

“Stringent quality norms driven by good clinical laboratory practise (GCLP) guidelines are being followed as mandated by regulatory authorities. The lab has renowned experts in each field who are working tirelessly and collectively to provide quality and timely results to fulfil the imminent need of an effective and safe COVID-19 vaccine,” the statement said. PTI

Top Stories

Bihar’s provisional voter turnout 53.54 pc in first phase, slightly lower than 2015

Bihar’s provisional voter turnout 53.54 pc in first phase, slightly lower than 2015

71 assembly segments of the state’s 243 constituencies voted...

Conducting Bihar elections amid pandemic ‘leap of faith’ for poll panel: CEC Arora

Conducting Bihar elections amid pandemic ‘leap of faith’ for poll panel: CEC Arora

Some opposition parties had urged the poll panel to postpone...

Indian troops standing firm; talks with China to continue: Rajnath Singh

Indian troops standing firm; talks with China to continue: Rajnath Singh

Defence minister addresses top commanders of Army

China says border standoff with India bilateral issue; criticises US’ Indo-Pacific strategy

China says border standoff with India bilateral issue; criticises US’ Indo-Pacific strategy

Situation across the border is generally stable: Foreign Min...

I-T dept seizes Rs 62 crore in cash after raids on hawala operatives in Punjab, Haryana, Delhi

I-T dept seizes Rs 62 crore in cash after raids on hawala operatives in Punjab, Haryana, Delhi

The cash, in crisp Rs 2,000 and Rs 500 notes, was found stas...

Cities

View All